[Dopamine agonist in the treatment of Parkinson's disease].
In the review paper is discussed the group of dopamine agonists which act directly on the postsynaptic receptors in the striatum, and have been used since over 20 years in the treatment of various stages of Parkinson's disease. For practical reasons they are divided in the paper into three groups: drugs used formerly and now gradually withdrawn mainly because of various adverse effects, new drugs whose effectiveness and usefulness have not yet been confirmed clinically, and three drugs (bromocriptine, lisuride, pergolide) used fairly widely with clinically confirmed effectiveness. The mechanism of their action and clinical results are described.
Kuran
W
W
I Kliniki Neurologicznej IPiN w Warszawie.
D001971:Bromocriptine / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000627:therapeutic use*; D006801:Humans; D008090:Lisuride / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000627:therapeutic use*; D012720:Severity of Illness Index
D018491:Dopamine Agonists; D010479:Pergolide; D001971:Bromocriptine; D008090:Lisuride